Nektar Therapeutics Faces Securities Fraud Lawsuit Amid Critical Phase 3 Financing and Trial Timeline

What happened

Bernstein Liebhard LLP announced a securities class action lawsuit against Nektar Therapeutics, covering investors who purchased securities between February 26, 2025, and December 15, 2025. This period aligns with Nektar's Phase 2b trial results for rezpegaldesleukin in atopic dermatitis, which drove significant stock price appreciation from around $10 to over $65 by early 2026. According to the DeepValue report, Nektar is now in a precarious position, focused on executing a $300 million equity raise and initiating FDA-aligned Phase 3 trials in Q2 2026 to prove durability and dosing convenience. The lawsuit alleges securities fraud, potentially stemming from misrepresentations or omissions during clinical data releases and financing activities, as highlighted in filings showing high cash burn and dependency on equity issuance. This legal action introduces a new overhang to an investment thesis already reliant on flawless capital market execution and timely clinical milestones, with no margin of safety at current prices.

Implication

Investors must now factor in potential legal costs and settlements that could strain Nektar's limited cash reserves, already under pressure from high operational burn rates. Management distraction from the lawsuit may delay the Phase 3 trial start beyond Q2 2026, a key thesis breaker identified in the report. The allegations could erode investor confidence, making it harder to complete the equity offering on favorable terms and increasing dilution risk. If the lawsuit reveals material misstatements, it might trigger regulatory scrutiny and reputational damage, further complicating clinical and commercial positioning. Overall, this reinforces the WAIT rating by heightening the stakes around financing and operational execution, with downside risks now including legal fallout.

Thesis delta

The original thesis advised waiting for clarity on the $300 million equity raise and Phase 3 trial start before investing, given high dependency on external funding and clinical timelines. With the securities fraud lawsuit, the risk profile has shifted negatively, introducing legal liabilities and management distraction that could directly impede these critical events. This reinforces the need to remain on the sidelines until both the legal situation resolves and operational milestones are verifiably met, as any misstep could cascade into further dilution or delays.